THE APEX TIMES
A new industry report added to ResearchAndMarkets’ catalog projects rapid growth for AI-based tools that help match patients to clinical trials, citing expected scale gains through 2032 and naming Microsoft among the vendors positioned in the space.
A new ResearchAndMarkets report added this week and promoted through a Yahoo Finance posting is pointing to fast growth in AI-based clinical trial solutions focused on patient matching, a task that involves identifying which patients are likely to meet a trial’s eligibility criteria and reducing the time it takes to enroll studies.
The announcement, dated Nov. 18, 2026, frames the market around artificial intelligence used to speed up and improve “patient matching” workflows in clinical research, and it highlights a projected growth trajectory through 2032. It does not describe a specific product launch or contract award by Microsoft in the release itself.
Instead, the posting functions as a catalog update for a packaged industry analysis. It states that the global market for AI-based clinical trial solutions for patient matching is expected to reach $3.4 billion in total revenue by 2032, and it cites a 25% compound annual growth rate as the basis for that outlook.
The same listing also names several companies that the report says are active or positioned in the category. Alongside Microsoft, the announcement references Medidata, ConcertAI, and, indicating that the report’s scope spans both established clinical trial software vendors and newer AI-focused players.
Microsoft’s inclusion appears to be tied to its broader role in providing cloud and AI capabilities to healthcare and life sciences customers, rather than to any one deal disclosed in the Yahoo Finance posting. The announcement does not specify which Microsoft services, models, or clinical trial customers are involved, and it does not provide implementation details or pricing.
For the broader sector, patient matching has become a practical bottleneck for sponsors trying to run studies efficiently. Eligibility criteria can be complex, data may be fragmented across systems, and recruitment timelines can drive costs and delay timelines for drug and device development. AI-based approaches are increasingly marketed as a way to connect relevant patient data to trial requirements more quickly.
Still, the disclosure in the promotion is limited. It does not provide methodology details behind the $3.4 billion forecast, it does not state whether the figure reflects software, services, or both, and it does not identify any measurable traction from Microsoft or the other named companies.
What to watch next is whether Microsoft, Medidata, or the other companies named in the report publish product updates, customer case studies, or earnings commentary that tie their efforts to patient matching outcomes, such as reduced screening failure rates or shorter enrollment cycles. Absent that, the immediate takeaway is the market narrative and the competitive field the analysis is highlighting.
Investors moved quickly after early outlines connected United Launch Alliance’s work to the BE-4 engine family, which Blue Origin’s New Glenn is expected to use for a planned 2027 flight carrying AST SpaceMobile’s BlueBird satellites.
A report tied to Anthropic’s debut highlights a cash position large enough to dwarf the combined figures of Amazon and NVIDIA, while also pointing to a new exchange-traded fund built around companies described as “ANT-linked.”
A Yahoo Finance report highlights how Berkshire Hathaway’s roughly $10 billion investment in Alphabet appears to be losing value, with Bill Ackman commenting that the timing and pricing were unexpected even as he noted the stake was bought at a perceived discount.
The company said it has reshaped leadership around national security and export-control oversight after Huang’s exit, emphasizing governance changes ahead of its next quarter and the continuing geopolitical scrutiny on advanced chips.
Anthropic priced its IPO at $83 per share ahead of its debut, while Nvidia heads toward a seventh straight weekly decline amid fresh US pressure on AI chip exports.
A report citing Cathie Wood’s ARK funds says they sold about $84.8 million of Nvidia shares before the company’s earnings period and used the cash to buy holdings tied to crypto markets.
Reports tied to Nvidia’s former chief executive, including allegations of multiple affairs involving a suspected Chinese intelligence-linked figure, are now being read alongside a broader, politically sensitive backdrop for advanced chip sales across the United States and China.
A celebrity investor publicly criticized NVIDIA’s former CEO Jensen Huang, then appeared to reverse course several days later, echoing a message that Nvidia employees “know better than the board,” according to a Yahoo Finance report.
A reporting update says the major banks and asset managers that earlier this year promised as much as $500 billion in financing support for Nvidia customers have not yet moved capital into that program.
The sale, disclosed in a regulatory filing, trims Lisa Su’s direct stake in Advanced Micro Devices while the company’s shares have climbed sharply this year.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...